argenx NV ADR (ARGX)vsOpus Genetics, Inc. (IRD)
ARGX
argenx NV ADR
$909.50
+5.82%
HEALTHCARE · Cap: $56.45B
IRD
Opus Genetics, Inc.
$4.18
+5.26%
HEALTHCARE · Cap: $339.35M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 39477% more annual revenue ($4.74B vs $11.98M). ARGX leads profitability with a 31.4% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
IRD
Avoid19
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.1%
Fair Value
$2204.33
Current Price
$909.50
$1294.83 discount
Margin of Safety
+45.1%
Fair Value
$5.99
Current Price
$4.18
$1.81 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Conservative balance sheet, low leverage
Areas to Watch
Weak financial health signals
Premium valuation, high expectations priced in
Trading at 192.3x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : IRD
The strongest argument for IRD centers on Debt/Equity.
Bear Case : ARGX
The primary concerns for ARGX are Piotroski F-Score, P/E Ratio, Price/Book. A P/E of 40.2x leaves little room for execution misses.
Bear Case : IRD
The primary concerns for IRD are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ARGX profiles as a growth stock while IRD is a value play — different risk/reward profiles.
IRD carries more volatility with a beta of 0.55 — expect wider price swings.
ARGX is growing revenue faster at 62.6% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (73/100 vs 19/100), backed by strong 31.4% margins and 62.6% revenue growth. IRD offers better value entry with a 45.1% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Opus Genetics, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Opus Genetics, Inc. (IRD) is a leading biotechnology firm focused on developing innovative gene therapies for rare retinal diseases impacting vision. By leveraging advanced gene-editing technologies and a robust research foundation, Opus aims to fulfill critical unmet medical needs in ocular health. With a promising pipeline supported by active clinical trials and strategic collaborations, the company is well-positioned to make significant contributions to patient care while presenting compelling growth opportunities for institutional investors in the dynamic healthcare landscape.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?